Wire Stories
-
356Research Report on China’s Titanium Dioxide Export Report, Analysis 2018-2022 & Outlook 2023-2032 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Research Report on China’s Titanium Dioxide Export 2023-2032” report has been added to ResearchAndMarkets.com’s offering. Titanium dioxide, also known as...
-
383Asia Pacific Glycomic Therapeutics Market Report 2023: Featuring Biomarin Pharmaceutical, Genzyme, Bayer, Glaxosmithkline & F. Hoffmann-La Roche – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of...
-
404Genius Group Signs Term Sheet for US$7.5 Million Share Subscription and Purchase Agreement
SINGAPORE–(BUSINESS WIRE)–$GNS #GNS—Genius Group Limited (NYSE American: GNS) (�Genius Group� or the �Company�), a leading entrepreneur edtech and education group, signed a...
-
394Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA...
-
414Citi Appointed as Depositary Bank for the GDR Program of Jiangsu Eastern Shenghong Co., Ltd.
Continued Participation in China-Swiss Stock Connect GDR Program NEW YORK–(BUSINESS WIRE)–Citi�s Issuer Services, acting through Citibank, N.A., has been appointed by Jiangsu...
-
393Cloudflare Announces New Solutions to Help CIOs Maximize Employee Collaboration and Productivity
Digital Experience Monitoring will provide unparalleled visibility and insights to businesses in the age of remote work SAN FRANCISCO–(BUSINESS WIRE)–Cloudflare, Inc. (NYSE:...
-
373FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
FSD Pharma Inc Announces Three Key Additions to Scientific and Clinical Expert Committee FSD Pharma Inc Announces It Is Investigating Other Products...
-
377Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
? Fibrosis regression observed in 50% of patients receiving fazirsiran ? Median reductions of 94% of Z-AAT accumulation in the liver and...
-
384STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022
ICL Unit Growth of 20% Y/Y for the Fourth Quarter and 33% Y/Y for Fiscal 2022 U.S. ICL Units Up 109% Y/Y...
-
386Zai Lab Appoints Michel Vounatsos�To Its Board of Directors
SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that Michel Vounatsos...
